This trial is no longer enrolling. This may mean the trial is fully enrolled, or that enrolment in the trial has been halted or suspended. You cannot enrol in this trial.
About this trial
The purpose of these studies is to investigate the efficacy, safety, and tolerability of raltegravir - a new drug from the new class of integrase inhibitors. These studies will compare a raltegravir-based regimen with a lopinavir-based one.
| Official title: | A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B |
|---|---|
| What is this trial studying? | New drug |
| How many participants will this trial enrol? | 340 The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic. |
| How long is this trial planned to go for? | Participants in this trial will be asked to take the trial drug for 48 weeks. |
| Who can enrol in this trial? | You may be eligible to participate in this trial if you meet the following criteria:
|
| Links to further information: | |
| Can I access this treatment other than by enrolling in this trial? | Raltegravir is listed on PBS from 1 July 2008 |
| Keywords: | lopinavir, raltegravir, ritonavir |
While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.
- Before making the decision to participate in any clinical research, read our background information.
- Email NAPWA if you have any questions or comments about this trial
- Call the Treataware info line if you need further advice
This factsheet, produced by Positive Life NSW, provides you with information and some questions to ask if you are considering participating in a clinical trial.